公开(公告)号：US20190015441A1

公开(公告)日：2019-01-17

申请号：US16068172

申请日：2017-01-05

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Idit SHACHAR ,  Hadas LEWINSKY ,  Lihi RADOMIR ,  Anna WIENER

IPC: A61K31/713 ,  A61K38/17 ,  A61P29/00 ,  A61P35/02 ,  A61P37/06

CPC classification number: A61K31/713 ,  A61K38/1774 ,  A61K2039/505 ,  A61P29/00 ,  A61P35/02 ,  A61P37/06 ,  C07K16/2896 ,  C07K2317/76

Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.

公开(公告)号：US20240398847A1

公开(公告)日：2024-12-05

申请号：US18668337

申请日：2024-05-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit SHACHAR ,  Hadas LEWINSKY ,  Lihi RADOMIR ,  Anna WIENER

IPC: A61K31/713 ,  A61K38/17 ,  A61K39/00 ,  A61P29/00 ,  A61P35/02 ,  A61P37/06 ,  C07K16/28

Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.

公开(公告)号：US20210052626A1

公开(公告)日：2021-02-25

申请号：US17089769

申请日：2020-11-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit SHACHAR ,  Hadas LEWINSKY ,  Lihi RADOMIR ,  Anna WIENER

IPC: A61K31/713 ,  C07K16/28 ,  A61P37/06 ,  A61P35/02 ,  A61P29/00 ,  A61K38/17

Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.

公开(公告)号：US20200263135A1

公开(公告)日：2020-08-20

申请号：US16762164

申请日：2018-11-14

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit SHACHAR ,  Shirly HERMAN

IPC: C12N5/0789 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K35/28

Abstract: A method of generating hematopoietic stem cells for transplantation is disclosed. The method comprising: (a) collecting hematopoietic stem cells; and (b) contacting the hematopoietic stem cells with an agent capable of decreasing an activity or expression of CD74 and/or of macrophage migration inhibitory factor (MIF), to thereby generate hematopoietic stem cells for transplantation, and wherein the hematopoietic stem cells are not transduced with a lentivirus. Methods of increasing mobilization of hematopoietic stem cells and methods of treatment are also provided.

公开(公告)号：US20180327493A1

公开(公告)日：2018-11-15

申请号：US16048422

申请日：2018-07-30

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit SHACHAR ,  Inbal BINSKY ,  Ayelet MAROM

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/50 ,  G01N33/574

CPC classification number: C07K16/2806 ,  C07K16/2896 ,  C07K16/3061 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/5011 ,  G01N33/57426 ,  G01N2333/70507 ,  G01N2500/10

Abstract: An isolated antibody comprising an antigen recognition domain which specifically binds CD84 and (i) down regulates the anti-apoptotic activity of stromal cells on chronic lymphocytic leukemia (CLL) cells; and/or (ii) induces mobilization of CLL cells from the bone marrow. Also provided are antibodies comprising antigen recognition domains comprising complementarity determining regions as indicated and uses thereof.

公开(公告)号：US20170260270A1

公开(公告)日：2017-09-14

申请号：US15116276

申请日：2015-02-05

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Idit SHACHAR ,  Inbal BINSKY ,  Ayelet MAROM

IPC: C07K16/28 ,  G01N33/574 ,  G01N33/50 ,  C07K16/30

CPC classification number: C07K16/2806 ,  C07K16/2896 ,  C07K16/3061 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/5011 ,  G01N33/57426 ,  G01N2333/70507 ,  G01N2500/10

Abstract: An isolated antibody comprising an antigen recognition domain which specifically binds CD84 and (i) down regulates the anti-apoptotic activity of stromal cells on chronic lymphocytic leukemia (CLL) cells; and/or (ii) induces mobilization of CLL cells from the bone marrow. Also provided are antibodies comprising antigen recognition domains comprising complementarity determining regions as indicated and uses thereof.

公开(公告)号：US20150344972A1

公开(公告)日：2015-12-03

申请号：US14827337

申请日：2015-08-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit SHACHAR ,  Inbal BINSKY ,  Mirko SOBOTTA

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K38/00 ,  C07K14/70596 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/57426 ,  G01N2333/70507

Abstract: A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL.

Abstract translation: 提供了在有需要的受试者中诊断B-CLL的方法。 该方法包括在受试者的生物样品中测定CD84同种型C（SEQ ID NO：30）的水平，其中相对于CD84同种型C（SEQ ID NO：30）的CD84同种型C（SEQ ID NO：30）的水平增加超过预定阈值 来自健康个体的生物样品中的CD84水平表示B-CLL。

公开(公告)号：US20140147451A1

公开(公告)日：2014-05-29

申请号：US14172926

申请日：2014-02-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit SHACHAR ,  Inbal Binsky ,  Mirko Sobotta

IPC: C07K16/28 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K38/00 ,  C07K14/70596 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/57426 ,  G01N2333/70507

Abstract: A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL.

Abstract translation: 提供了在有需要的受试者中诊断B-CLL的方法。 该方法包括在受试者的生物样品中测定CD84同种型C（SEQ ID NO：30）的水平，其中相对于CD84同种型C（SEQ ID NO：30）的CD84同种型C（SEQ ID NO：30）的水平增加超过预定阈值 来自健康个体的生物样品中的CD84水平表示B-CLL。